CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade PharmaCyte Biotech, Inc. - PMCB CFD

2.15
0.46%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2.16
Open* 2.13
1-Year Change* -14.8%
Day's Range* 2.06 - 2.15
52 wk Range 2.30-3.23
Average Volume (10 days) 16.33K
Average Volume (3 months) 561.04K
Market Cap 20.54M
P/E Ratio -100.00K
Shares Outstanding 8.78M
Revenue N/A
EPS -0.21
Dividend (Yield %) N/A
Beta -0.01
Next Earnings Date Sep 25, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 26, 2023 2.15 0.02 0.94% 2.13 2.15 2.06
Sep 25, 2023 2.16 -0.08 -3.57% 2.24 2.24 2.16
Sep 22, 2023 2.31 -0.01 -0.43% 2.32 2.33 2.22
Sep 21, 2023 2.28 -0.06 -2.56% 2.34 2.34 2.28
Sep 20, 2023 2.32 0.00 0.00% 2.32 2.38 2.29
Sep 19, 2023 2.44 0.07 2.95% 2.37 2.50 2.37
Sep 18, 2023 2.52 0.07 2.86% 2.45 2.52 2.32
Sep 15, 2023 2.46 0.05 2.07% 2.41 2.49 2.40
Sep 14, 2023 2.56 0.12 4.92% 2.44 2.58 2.44
Sep 13, 2023 2.45 0.03 1.24% 2.42 2.46 2.34
Sep 12, 2023 2.41 0.05 2.12% 2.36 2.43 2.33
Sep 11, 2023 2.44 0.00 0.00% 2.44 2.45 2.40
Sep 8, 2023 2.44 0.12 5.17% 2.32 2.46 2.32
Sep 7, 2023 2.32 -0.01 -0.43% 2.33 2.37 2.28
Sep 6, 2023 2.35 0.03 1.29% 2.32 2.39 2.32
Sep 5, 2023 2.38 -0.05 -2.06% 2.43 2.45 2.36
Sep 1, 2023 2.46 0.01 0.41% 2.45 2.46 2.38
Aug 31, 2023 2.43 0.04 1.67% 2.39 2.44 2.35
Aug 30, 2023 2.42 0.04 1.68% 2.38 2.43 2.34
Aug 29, 2023 2.42 0.08 3.42% 2.34 2.44 2.33

PharmaCyte Biotech, Inc. Events

Time (UTC) Country Event
Monday, December 11, 2023

Time (UTC)

21:00

Country

US

Event

Q2 2024 PharmaCyte Biotech Inc Earnings Release
Q2 2024 PharmaCyte Biotech Inc Earnings Release

Forecast

-

Previous

-
Thursday, December 28, 2023

Time (UTC)

15:00

Country

US

Event

PharmaCyte Biotech Inc Annual Shareholders Meeting
PharmaCyte Biotech Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Cost of Revenue, Total
Gross Profit
Total Operating Expense 6.45549 4.39201 3.547 3.8264 4.10063
Selling/General/Admin. Expenses, Total 5.98696 3.70108 2.70673 3.52517 3.64058
Research & Development 0.46854 0.69094 0.91625 0.30122 0.46005
Unusual Expense (Income) 0 -0.07598
Operating Income -6.45549 -4.39201 -3.547 -3.8264 -4.10063
Interest Income (Expense), Net Non-Operating 1.9375 0.15714 -0.00305 -0.00045
Other, Net 0.202 -0.00428 -0.00119 -0.00004 0.0334
Net Income Before Taxes -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
Net Income After Taxes -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
Net Income Before Extra. Items -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
Net Income -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
Income Available to Common Excl. Extra. Items -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
Income Available to Common Incl. Extra. Items -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
Diluted Net Income -4.31599 -4.23916 -3.55124 -3.82689 -4.06723
Diluted Weighted Average Shares 19.4892 15.5217 1.44829 0.90833 0.73707
Diluted EPS Excluding Extraordinary Items -0.22146 -0.27311 -2.45203 -4.2131 -5.5181
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.22146 -0.27311 -2.50449 -4.2131 -5.5181
Total Extraordinary Items
Apr 2023 Jan 2023 Oct 2022 Jul 2022 Apr 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 0.90328 1.55298 2.31862 1.68061 1.5077
Selling/General/Admin. Expenses, Total 0.81741 1.50759 2.14062 1.52134 1.25364
Research & Development 0.08587 0.04539 0.178 0.15927 0.25407
Operating Income -0.90328 -1.55298 -2.31862 -1.68061 -1.5077
Interest Income (Expense), Net Non-Operating 0.72294 0.63589 0.43917 0.1395 0.08657
Other, Net 0.05401 0.15296 -0.00106 -0.00391 -0.00157
Net Income Before Taxes -0.12634 -0.76414 -1.88051 -1.54501 -1.42271
Net Income After Taxes -0.12634 -0.76414 -1.88051 -1.54501 -1.42271
Net Income Before Extra. Items -0.12634 -0.76414 -1.88051 -1.54501 -1.42271
Net Income -0.12634 -0.76414 -1.88051 -1.54501 -1.42271
Income Available to Common Excl. Extra. Items -0.12634 -0.76414 -1.88051 -1.54501 -1.42271
Income Available to Common Incl. Extra. Items -0.12634 -0.76414 -1.88051 -1.54501 -1.42271
Diluted Net Income -0.12634 -0.76414 -1.88051 -1.54501 -1.42271
Diluted Weighted Average Shares 17.802 18.9954 20.5854 20.8293 21.4702
Diluted EPS Excluding Extraordinary Items -0.0071 -0.04023 -0.09135 -0.07417 -0.06626
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.0071 -0.04023 -0.09135 -0.07417 -0.06626
Unusual Expense (Income) 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 85.4948 2.27524 1.03765 0.6534 1.28387
Cash and Short Term Investments 85.4007 2.20211 0.89486 0.51525 1.0598
Cash 85.4007 2.20211 0.89486 0.51525 1.0598
Prepaid Expenses 0.09417 0.07313 0.14279 0.13815 0.22407
Total Assets 90.6241 7.40423 6.16664 5.7824 6.41286
Intangibles, Net 3.54943 3.54943 3.54943 3.54943 3.54943
Long Term Investments 1.57219 1.57219 1.57219 1.57219 1.57219
Other Long Term Assets, Total 0.00769 0.00737 0.00737 0.00737 0.00737
Total Current Liabilities 0.70437 0.72478 1.0314 0.74285 0.64417
Accounts Payable 0.20536 0.17226 0.18584 0.12189 0.35262
Accrued Expenses 0.49901 0.55252 0.81664 0.62097 0.29155
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 0.70437 0.72478 1.07768 0.74285 0.64417
Total Long Term Debt 0 0 0.04628 0 0
Total Equity 89.9198 6.67945 5.08896 5.03955 5.76869
Common Stock 0.00207 0.00016 0.16386 0.1186 0.10133
Additional Paid-In Capital 201.582 114.109 108.805 104.966 101.636
Retained Earnings (Accumulated Deficit) -111.649 -107.41 -103.858 -100.031 -95.9641
Other Equity, Total -0.01576 -0.02038 -0.02171 -0.01384 -0.00471
Total Liabilities & Shareholders’ Equity 90.6241 7.40423 6.16664 5.7824 6.41286
Total Common Shares Outstanding 20.7211 1.59008 1.09789 0.79462 0.67888
Current Port. of LT Debt/Capital Leases 0 0.02892
Long Term Debt 0 0.04628
Jan 2023 Oct 2022 Jul 2022 Apr 2022 Jan 2022
Total Current Assets 72.8212 77.2194 82.2558 85.4948 86.8139
Cash and Short Term Investments 72.6402 76.9626 82.2276 85.4007 86.6398
Cash 72.6402 76.9626 82.2276 85.4007 86.6398
Prepaid Expenses 0.18101 0.25681 0.02815 0.09417 0.1741
Total Assets 77.9505 82.3487 87.3851 90.6241 91.9432
Intangibles, Net 3.54943 3.54943 3.54943 3.54943 3.54943
Long Term Investments 1.57219 1.57219 1.57219 1.57219 1.57219
Other Long Term Assets, Total 0.00769 0.00769 0.00769 0.00769 0.00769
Total Current Liabilities 0.82783 1.31113 1.08936 0.70437 0.61298
Accounts Payable 0.44594 0.86128 0.55903 0.20536 0.09286
Accrued Expenses 0.3819 0.44986 0.53033 0.49901 0.52012
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Total Liabilities 0.82783 1.31113 1.08936 0.70437 0.61298
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Total Equity 77.1227 81.0376 86.2957 89.9198 91.3302
Common Stock 0.00216 0.00216 0.00216 0.00207 0.00207
Additional Paid-In Capital 202.231 201.601 201.593 201.582 201.573
Retained Earnings (Accumulated Deficit) -115.838 -115.074 -113.194 -111.649 -110.226
Other Equity, Total -0.01773 -0.01517 -0.01445 -0.01576 -0.0193
Total Liabilities & Shareholders’ Equity 77.9505 82.3487 87.3851 90.6241 91.9432
Total Common Shares Outstanding 18.209 20.7211 20.7501 20.7211 20.7202
Treasury Stock - Common -9.25401 -5.47589 -2.09085
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -4.23916 -3.55124 -3.82689 -4.06723 -6.82884
Cash From Operating Activities -4.11732 -3.33089 -2.33837 -2.87791 -5.0794
Non-Cash Items 0.1128 0.36596 1.22117 1.02222 1.83532
Cash Interest Paid 0.00051 0.00227 0.00045
Changes in Working Capital 0.00904 -0.14561 0.26735 0.1671 -0.08587
Cash From Investing Activities 0 0 0 0 0
Other Investing Cash Flow Items, Total 0 0 0 0 0
Cash From Financing Activities 87.3112 4.63681 2.72585 2.3425 2.68141
Issuance (Retirement) of Stock, Net 87.3621 4.69925 2.663 2.3425 2.68141
Issuance (Retirement) of Debt, Net -0.05081 -0.06244 0.06285
Foreign Exchange Effects 0.00463 0.00133 -0.00787 -0.00913 -0.00645
Net Change in Cash 83.1985 1.30725 0.37961 -0.54455 -2.40443
Cash Taxes Paid 0.0016 0.0008 0.0008
Jan 2023 Oct 2022 Jul 2022 Apr 2022 Jan 2022
Net income/Starting Line -4.18966 -3.42552 -1.54501 -4.23916 -2.81645
Cash From Operating Activities -3.50534 -2.96364 -1.08438 -4.11732 -2.92548
Non-Cash Items 0.81355 0.01775 0.00962 0.1128 0.10406
Cash Taxes Paid 0 0 0 0.0016 0.0016
Cash Interest Paid 0 0 0 0.00051 0.00051
Changes in Working Capital -0.12924 0.44413 0.45101 0.00904 -0.21309
Cash From Investing Activities 0 0 0 0
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities -9.25313 -5.47501 -2.08997 87.3112 87.3621
Issuance (Retirement) of Stock, Net -9.25313 -5.47501 -2.08997 87.3621 87.3621
Issuance (Retirement) of Debt, Net -0.05081 0
Foreign Exchange Effects -0.00197 0.00058 0.0013 0.00463 0.00108
Net Change in Cash -12.7604 -8.43807 -3.17304 83.1985 84.4377

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

PharmaCyte Biotech, Inc. Company profile

About Pharmacyte Biotech Inc

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The Company's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. It also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The Company is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Pharmacyte Biotech Inc revenues was not reported. Net loss increased 9% to $2.8M. Higher net loss reflects General and administrative increase from $291K to $836K (expense), Legal and professional increase of 85% to $601K (expense), Director fees increase of 1% to $209K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.88 to -$0.74.

Equity composition

Common Stock $0.0001 Par, 03/11, 500M auth., 353,387,581 issd. Insiders own 9.09%. 12/03, 3 for 1 forward stock split. 03/09, Name changed from eFoodSafety.com Inc. Preferred Stock $.0001 Par, 10M auth., 5K issd.

Industry: Pharmaceuticals (NEC)

3960 Howard Hughes Parkway, Suite 500
LAS VEGAS
NEVADA 89169
US

Income Statement

  • Annual
  • Quarterly

News

USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

People also watch

XRP/USD

0.51 Price
+0.770% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Oil - Crude

91.63 Price
+1.550% 1D Chg, %
Long position overnight fee 0.0436%
Short position overnight fee -0.0655%
Overnight fee time 21:00 (UTC)
Spread 0.030

US100

14,607.30 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

26,828.00 Price
+2.370% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading